title: Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study.
abstract: This study was undertaken to determine whether selected risk factors for esophageal and gastric cancer are associated with tumors that overexpress cyclin D1. Archived tumor tissue was available for 630 esophageal and gastric cancer patients who participated in a population-based case-control study. Patients were categorized into case groups based on whether protein overexpression of the cyclin D1 gene, as assessed by immunohistochemistry, was present (cyclin D1+, n = 285) or not (cyclin D1-, n = 345) in the tumor. The distribution of risk factors in each of these case groups was then compared with the distribution among the 695 controls. Multivariate-adjusted odds ratios (OR) for esophageal adenocarcinoma were reduced in relation to use of aspirin and other nonsteroidal anti-inflammatory drug (NSAID) use but only among patients with cyclin D1+ tumors (0.45, 95% confidence interval [CI] = 0.26, 0.79) and not among those with cyclin D1- tumors (1.12, 95% CI = 0.67, 1.86). A similar pattern was observed for gastric cardia adenocarcinomas. In contrast, ORs for esophageal squamous cell carcinoma and noncardia gastric adenocarcinomas in relation to NSAID use were reduced, regardless of cyclin D1 status. ORs did not vary with cyclin D1 status in relation to alcohol, body size, or cigarette smoking, with the following exception; for noncardia gastric adenocarcinomas the cyclin D1- tumors showed a 2-fold elevation in the OR with ever smoking. These data suggest that the reduction in risk associated with NSAID use may be restricted to those esophageal and gastric cardia adenocarcinomas that overexpress cyclin D1.
authors.affiliation: University of North Carolina, School of Public Health, Department of Epidemiology, Chapel Hill, North Carolina, USA. gammon@unc.edu
authors.forename: Marilie D
authors.initials: MD
authors.lastname: Gammon
authors.forename: Mary Beth
authors.initials: MB
authors.lastname: Terry
authors.forename: Nadir
authors.initials: N
authors.lastname: Arber
authors.forename: Wong-Ho
authors.initials: WH
authors.lastname: Chow
authors.forename: Harvey A
authors.initials: HA
authors.lastname: Risch
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Vaughan
authors.forename: Janet B
authors.initials: JB
authors.lastname: Schoenberg
authors.forename: Susan T
authors.initials: ST
authors.lastname: Mayne
authors.forename: Janet L
authors.initials: JL
authors.lastname: Stanford
authors.forename: Robert
authors.initials: R
authors.lastname: Dubrow
authors.forename: Heidrun
authors.initials: H
authors.lastname: Rotterdam
authors.forename: A Brian
authors.initials: AB
authors.lastname: West
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Fraumeni
authors.forename: I Bernard
authors.initials: IB
authors.lastname: Weinstein
authors.forename: Hanina
authors.initials: H
authors.lastname: Hibshoosh
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D016001:Confidence Intervals; D019938:Cyclin D1 / Q000378:metabolism*; D004938:Esophageal Neoplasms / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D005260:Female; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D015995:Prevalence; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D011795:Surveys and Questionnaires; D014481:United States / Q000453:epidemiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019938:Cyclin D1